EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK
Abstract
Authors
B. Miller M. Russel-Szymczyk I.S. Jensen A. Shah S.T. Alexopoulos A. Herbert T. McLean N. Tundia